Literature DB >> 27120117

Inhibitory RNA Aptamers of Tau Oligomerization and Their Neuroprotective Roles against Proteotoxic Stress.

Ji Hyeon Kim1,2, Eunkyoung Kim1, Won Hoon Choi1,2, Jeeyoung Lee1,2, Jung Hoon Lee1, Hyojin Lee2,3, Dong-Eun Kim4, Young Ho Suh2,3, Min Jae Lee1,2,5.   

Abstract

Tau is a cytosolic protein that functions in the assembly and stabilization of axonal microtubule networks. Its oligomerization may be the rate-limiting step of insoluble aggregate formation, which is a neuropathological hallmark of Alzheimer's disease (AD) and a number of other tauopathies. Recent evidence indicates that soluble tau oligomers are the toxic species for tau-mediated pathology during AD progression. Herein, we describe novel RNA aptamers that target human tau and were identified through an in vitro selection process. These aptamers significantly inhibited the oligomerization propensity of tau both in vitro and in cultured cell models of tauopathy without affecting the half-life of tau. Tauopathy model cells treated with the aptamers were less sensitized to proteotoxic stress induced by tau overexpression. Moreover, the tau aptamers significantly alleviated synthetic tau oligomer-mediated neurotoxicity and dendritic spine loss in primary hippocampal neurons. Thus, our study demonstrates that delaying tau assembly with RNA aptamers is an effective strategy for protecting cells under various neurodegenerative stresses originating from pathogenic tau oligomerization.

Entities:  

Keywords:  Alzheimer’s disease; SELEX; aggregation; aptamer; inhibition; neurotoxicity; oligomerization; tau; tauopathy

Mesh:

Substances:

Year:  2016        PMID: 27120117     DOI: 10.1021/acs.molpharmaceut.6b00165

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  9 in total

Review 1.  Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing.

Authors:  Barry Boland; Wai Haung Yu; Olga Corti; Bertrand Mollereau; Alexandre Henriques; Erwan Bezard; Greg M Pastores; David C Rubinsztein; Ralph A Nixon; Michael R Duchen; Giovanna R Mallucci; Guido Kroemer; Beth Levine; Eeva-Liisa Eskelinen; Fanny Mochel; Michael Spedding; Caroline Louis; Olivier R Martin; Mark J Millan
Journal:  Nat Rev Drug Discov       Date:  2018-08-17       Impact factor: 84.694

2.  Identification and Characterization of DNA Aptamers Specific for Phosphorylation Epitopes of Tau Protein.

Authors:  I-Ting Teng; Xiaowei Li; Hamad Ahmad Yadikar; Zhihui Yang; Long Li; Yifan Lyu; Xiaoshu Pan; Kevin K Wang; Weihong Tan
Journal:  J Am Chem Soc       Date:  2018-10-16       Impact factor: 15.419

Review 3.  Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders.

Authors:  Islauddin Khan; Kumari Preeti; Valencia Fernandes; Dharmendra Kumar Khatri; Shashi Bala Singh
Journal:  Cell Mol Neurobiol       Date:  2021-05-01       Impact factor: 4.231

Review 4.  Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.

Authors:  Pascal Röthlisberger; Cécile Gasse; Marcel Hollenstein
Journal:  Int J Mol Sci       Date:  2017-11-16       Impact factor: 5.923

Review 5.  Degradation or aggregation: the ramifications of post-translational modifications on tau.

Authors:  Seoyoung Park; Jung Hoon Lee; Jun Hyoung Jeon; Min Jae Lee
Journal:  BMB Rep       Date:  2018-06       Impact factor: 4.778

6.  Modulation of α-Synuclein Aggregation In Vitro by a DNA Aptamer.

Authors:  Claire H Tran; Ranajay Saha; Celia Blanco; Damayanti Bagchi; Irene A Chen
Journal:  Biochemistry       Date:  2022-08-22       Impact factor: 3.321

Review 7.  Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.

Authors:  Madhuri Chakravarthy; Suxiang Chen; Peter R Dodd; Rakesh N Veedu
Journal:  Theranostics       Date:  2017-09-05       Impact factor: 11.556

Review 8.  Aptamer Applications in Neuroscience.

Authors:  Meric Ozturk; Marit Nilsen-Hamilton; Muslum Ilgu
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-03

Review 9.  RNA-based therapeutics for neurological diseases.

Authors:  Karen Anthony
Journal:  RNA Biol       Date:  2021-12-31       Impact factor: 4.652

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.